- Home
- TIL vs XGN Comparison
TIL vs XGN Comparison
Compare TIL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | XGN |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 74.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TIL | XGN |
|---|---|---|
| Price | $9.04 | $3.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $125.00 | $11.00 |
| AVG Volume (30 Days) | 41.1K | ★ 315.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.99 |
| Revenue Next Year | N/A | $11.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $2.80 |
| 52 Week High | $42.75 | $12.23 |
Technical Indicators
Market Signals| Indicator | TIL | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 37.22 |
| Support Level | $8.14 | $3.15 |
| Resistance Level | $9.81 | $4.00 |
| Average True Range (ATR) | 0.64 | 0.33 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 58.68 | 29.59 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.